Navigating the July 2026 PCAC Rulings: How to Keep Peptides in Your Practice

It's easy to read the July 2026 PCAC meeting as a single event with a single outcome still pending — FDA either says yes or says no, and a clinic's peptide menu either survives or doesn't. That's not quite the shape of what's actually happening. The July meeting was the first round of a series the FDA itself scheduled, with a second round of peptide reviews already on the calendar for before February 2027. This is a process a clinic needs to manage on an ongoing basis, not a verdict to wait out.

The practical question for an owner who wants to keep offering peptides isn't "will this get approved" — nobody outside FDA knows that yet. It's "what can my clinic actually build a defensible program around right now, and how do I stay positioned for whatever comes out of the next round." That's what this is about.

This Is Round One of a Longer Process

FDA's Pharmacy Compounding Advisory Committee reviewed seven peptide families across two days in July 2026 — BPC-157, KPV and TB-500 on July 23, and Emideltide, Semax and Epitalon on July 24 — and voted favorably on six of the seven. A second, already-scheduled round covers a different set of substances before February 2027: Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, and pegylated Mechano Growth Factor.

FDA is the final decision-maker on every recommendation to come out of either round, and as of this writing it has not acted on the six favorable July recommendations. Treating July as the finish line — and building a menu or a marketing plan around what "should" happen next — skips past the part of the process that actually determines what a clinic can legally do.

What You Can Actually Build a Program Around Today

A real peptide program doesn't have to sit empty while this plays out. It has to be built on what's currently authorized, not what's expected to be.

• FDA-approved peptide drugs: products that already cleared full FDA approval — insulin, GLP-1 medications, synthetic hormone analogs — carry no compounding-law question and can anchor a program on their own.
• Category 1 substances: a bulk substance FDA has not flagged a significant safety risk for currently sits on the Category 1 list, which carries an active enforcement-discretion policy permitting 503A compounding while formal review continues. GHK-Cu, added to Category 1 in May 2026, is a real, current example — not a pending one.
• Anything with an applicable USP or NF monograph: a smaller, more stable category, but one that doesn't depend on the PCAC calendar at all.

What to Hold, and How to Handle Existing Patients on It

BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax are not currently lawful to compound under 503A — a favorable recommendation is not a listing. If any of these were already on your menu, the responsible move is not to quietly keep going and hope the eventual FDA decision retroactively covers the gap. It's to have your medical director make the call explicitly, document the basis, and communicate a clear plan to any patient currently on one of these protocols — what's pausing, why, and what alternative (an FDA-approved option, or a Category 1 substance where clinically appropriate) is available in the meantime.

This is also where a documented "watch list" earns its keep: a short, specific record of which substances your clinic paused, why, and what would need to change — a Bulks List listing, a Category 1 move — before they're back on the table. That document is what turns "we're not sure, we stopped everything" into "we made a specific, defensible call on a specific date," which is the version a board or an inspector actually wants to see.

Staying Ready for What Changes Next

The clinics that handle this transition best aren't the ones betting on a particular outcome — they're the ones set up to move quickly and correctly whenever the next real change lands, in either direction. That means a pharmacy relationship with a partner who is already tracking Bulks List and Category status substance by substance, not one you'd have to go find after a listing happens. It means standing orders drafted in advance for the substances on your watch list, ready for your director's sign-off the moment the legal basis clears, instead of starting that paperwork from zero. And it means treating the February 2027 round the same way you should have treated July — as a date to be prepared for, not a surprise to react to.

Plan for FDA Rejecting a Recommendation, Too

FDA is not bound by the PCAC's recommendations and has already presented its own safety concerns against all seven substances reviewed in July, despite the committee's vote. A clinic that has told patients, staff or referral partners that a peptide is "on the way" because a committee recommended it is exposed if FDA ultimately declines to add it. The safer posture is to talk about what's currently available in plain, accurate terms, and to treat anything still pending as pending — genuinely undecided, in either direction — rather than as a formality.

Where MedGrid Fits

MedGrid keeps your peptide program built on what's actually authorized today, with a medical director who tracks the PCAC calendar and FDA's actions on it as part of your regular protocol review — not a one-time lookup. When the February 2027 round lands, or when FDA finally acts on the July recommendations, your clinic finds out from your own director on the same day, with a plan already drafted for what changes.

Frequently Asked Questions

• Is the July 2026 PCAC vote the final word on these peptides?: No. FDA is the final decision-maker and has not yet acted on the committee's six favorable recommendations. A second round of PCAC review for different substances is already scheduled before February 2027.
• Can my clinic keep offering BPC-157 while we wait for a final decision?: Not lawfully under 503A as of this writing — a favorable recommendation isn't a Bulks List listing. Talk to your medical director about pausing and documenting the basis, and about what's currently available instead.
• What can we actually offer while this plays out?: FDA-approved peptide drugs, and bulk substances currently in Category 1 — like GHK-Cu — which carry an active enforcement-discretion basis for compounding right now.
• What happens if FDA rejects the PCAC's recommendation?: Nothing changes for a clinic that never built its menu or its patient communication around an assumed approval. That's the safer posture regardless of which way the eventual decision goes.

This article is general educational information about FDA's ongoing peptide compounding review process, not legal advice for your specific clinic. The status of individual substances and the PCAC's review calendar are both subject to change — confirm current status with your medical director and licensed counsel before making a sourcing or patient-communication decision.